MBX Biosciences reports positive Phase 2 results for canvuparatide and posts Q3 financials
Reuters
Nov 06, 2025
<a href="https://laohu8.com/S/MBX">MBX Biosciences</a> reports positive Phase 2 results for canvuparatide and posts Q3 financials
MBX Biosciences Inc. reported cash, cash equivalents, and marketable securities of $391.7 million as of September 30, 2025, including proceeds from its recent public offering, which raised approximately $200 million in gross proceeds. Research and development expenses for the third quarter of 2025 were $19.3 million, up from $16.7 million in the same period of 2024. The increase was attributed to costs associated with ongoing clinical trials. The company announced positive topline results from the Phase 2 Avail trial of canvuparatide in hypoparathyroidism and completed an upsized public offering. MBX expects its cash position to support operations into 2029 and has outlined milestones for 2026, including Phase 3 trial initiation for canvuparatide and clinical data readouts for other pipeline programs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569963-en) on November 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.